Deepa Rangachari

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

A view on drug resistance in cancer

The biology and management of non-small cell lung cancer

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Understanding and targeting resistance mechanisms in NSCLC

Current and future perspectives of liquid biopsies in genomics-driven oncology

Targeting apoptosis in cancer therapy

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Tumour heterogeneity and resistance to cancer therapies

Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

Targeting ALK: Precision Medicine Takes on Drug Resistance

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression.